[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endometrial-serous-adenocarcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endometrial-serous-adenocarcinoma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100443065","determine-the-utility-of-liquid-biopsies-and-tumor-molecular-profiling-in-predicting-recurrence-in-endometrial-cancers-100443065",false,"NCT05049538","Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers","A Pilot Investigation to Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancer","Inclusion Criteria:\n\n* Women age 18 years and older\n* Histologic diagnosis of endometrial cancer\n* Candidate for primary surgical treatment or has recently had prior primary surgery\n* Willing and able to provide informed consent\n\nExclusion Criteria:\n\nPatients who have received prior treatment including chemotherapy or radiation therapy for endometrial cancer. Prior hormonal therapy for the treatment of endometrial cancer is allowed. Patients with prior primary surgery will be allowed to enroll in this trial if the patient has not received any chemotherapy or radiation at the time of enrollment. Note: patients with a history of other cancers may be enrolled after discussion with the PI if it is determined that they are at low risk for recurrence or metastasis.","FEMALE","18 Years",{"count":19,"type":20},1000,"ESTIMATED","OBSERVATIONAL","This study is to find out how well liquid biopsies work as a non-invasive alternative to other methods of finding cancer cells (such as a tissue biopsy) in patients with endometrial cancer. A liquid biopsy is a blood test that may be able to find cancer cells. Collecting and storing samples of blood and tissue from patients with endometrial cancer to study in the laboratory may help doctors learn how the cells in the blood may change during treatment for uterine cancer.",[24,25,26,27,28,29],"Endometrial Clear Cell Adenocarcinoma","Endometrial Dedifferentiated Carcinoma","Endometrial Mucinous Adenocarcinoma","Endometrial Serous Adenocarcinoma","Malignant Uterine Neoplasm","Uterine Corpus Carcinosarcoma","RECRUITING","2026-04-30",{"date":33,"type":34},"2026-05-06","ACTUAL",{"date":36,"type":34},"2019-06-18",{"date":38,"type":20},"2028-06-30",{"name":40,"class":41},"M.D. Anderson Cancer Center","OTHER",1,{"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":52,"minAge":4,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100318167","phase-3-short-course-vaginal-cuff-brachytherapy-in-treating-participants-with-stage-i-ii-endometrial-cancer-100318167",true,"NCT03422198","Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer","Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE)","SAVE","Inclusion Criteria:\n\n* Histologically confirmed endometrial carcinoma: endometrioid type, serous, and clear cell, to include tumors originating in the cervix, but are primarily located in the uterus, and for whom vaginal cuff brachytherapy is indicated. Carcinosarcoma and other sarcomas are permitted; Federation of Gynecology and Obstetrics (FIGO) stage I and stage II, with one of the following combinations of stage and grade:\n\n  * Stage IA, grade 1 with LVSI, 2, 3\n  * Stage IB, grades 1-3\n  * Stage II, grades 1-3\n  * Stage IIIA, grades 1-3, not receiving EBRT as part of adjuvant therapy.\n* Participants post-hysterectomy and free from residual disease.\n* World Health Organization (WHO)\u002FEastern Cooperative Oncology Group (ECOG)-performance status 0-2.\n* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.\n* Life expectancy of \\>2 years.\n\nExclusion Criteria:\n\n* Stages of endometrial carcinoma other than described.\n* Previous pelvic radiotherapy.\n* Concurrent malignancy requiring non-protocol anti-cancer treatment other than surgery.","ALL",{"count":54,"type":20},188,"INTERVENTIONAL",[57],"PHASE3","This randomized phase III trial studies short course vaginal cuff brachytherapy to see how well it works compared with standard of care vaginal cuff brachytherapy in treating participants with stage I-II endometrial cancer. Short course vaginal cuff brachytherapy, also known as internal radiation therapy, uses (over a shorter period) radioactive material placed directly into or near a tumor in the upper portion of the vagina to kill tumor cells.\n\nAfter completion of cohort 1 (108 participants), the protocol was expended to add a second cohort of 80 additional participants, and re-opened study recruitment.",[24,60,27,61,62,63,64,29,65],"Endometrial Endometrioid Adenocarcinoma","Stage I Uterine Corpus Cancer","Stage IA Uterine Corpus Cancer","Stage IB Uterine Corpus Cancer","Stage II Uterine Corpus Cancer","Uterine Corpus Sarcoma","2025-11-25",{"date":68,"type":34},"2025-12-12",{"date":70,"type":34},"2018-02-02",{"date":72,"type":20},"2029-10-31",{"name":74,"class":41},"University of Utah",5]